JavaScript is disabled in your browser. Please enable JavaScript to view this website.

TFAM

GeneName

TFAM

Summary

TFAM, also known as transcription factor 6, mtTFA, or mtTF1, is a 29 kDa mitochondrial protein that plays a pivotal role in the regulation of mitochondrial DNA transcription and replication. It is primarily localised in the mitochondrial matrix and nucleoid, where it binds to mitochondrial DNA to facilitate the assembly of the mitochondrial respiratory chain complexes. TFAM also exhibits chromatin binding activity and is involved in the positive regulation of DNA-templated transcription, particularly at mitochondrial promoters. Additionally, it has roles in cellular responses to hypoxia and nutrient availability.

Importance

TFAM is relevant to: - Mitochondrial dysfunction and associated diseases, including neurodegenerative disorders and metabolic syndromes, due to its essential role in mitochondrial DNA maintenance and transcription. - Ageing processes, as alterations in TFAM levels can impact mitochondrial biogenesis and function over time. - Cancer biology, where changes in mitochondrial gene expression may influence tumour metabolism and growth. - Studies of cellular responses to environmental stressors, such as hypoxia, highlighting its role in adaptive mechanisms.

Top Products

For researchers investigating TFAM, we recommend two excellent primary antibodies that cater to various experimental needs. The first is the well-cited polyclonal antibody, Anti-mtTFA antibody - Mitochondrial Marker (ab131607), which has garnered 172 citations, reflecting its strong reputation in the field. This antibody is particularly effective for Western blotting (WB), making it a reliable choice for protein detection.In addition, we offer the recombinant antibody, Anti-mtTFA antibody [EPR12285] - Mitochondrial Marker (ab176558). This product has been validated in knockout models and is suitable for a broader range of applications, including WB, immunohistochemistry (IHC), immunocytochemistry (ICC), and immunoprecipitation (IP). With 30 citations, it is gaining traction among researchers. The recombinant nature of this antibody ensures batch-to-batch consistency, making it an excellent option for those requiring dependable results in their TFAM studies.

Abcam Product Citation Summary

The data indicates that TFAM is frequently studied in the context of mitochondrial function and biogenesis across various species, particularly in mouse models. The applications primarily involve Western blotting, highlighting its importance in understanding mitochondrial DNA and gene expression, especially in conditions like diabetes, sepsis, and after ischemia-reperfusion injury.

Abcam Product Citation Table

ab119684
Rat
WB
Diabetic rats
29142323
ab119684
Mouse
WB
LRRK2 inhibition
34340748
ab131607
Mouse
WB
Heart tissue
29132502
ab131607
Mouse
WB
Sepsis-induced acute kidney injury
32131850
ab131607
Mouse
WB
Skeletal muscle homogenates
30122554
ab131607
Mouse
WB
Liver tissue after ischemia-reperfusion
30388684
ab131607
Mouse
WB
Cerebellum
29125827
ab131607
Mouse
WB
Quadriceps femoris muscle after endurance training
25821434
ab131607
Human
WB
U2OS cells
28900160

Domain

Binds DNA via its HMG boxes. When bound to the mitochondrial light strand promoter, bends DNA into a U-turn shape, each HMG box bending the DNA by 90 degrees.

Function

Binds to the mitochondrial light strand promoter and functions in mitochondrial transcription regulation (PubMed:29445193, PubMed:32183942). Component of the mitochondrial transcription initiation complex, composed at least of TFB2M, TFAM and POLRMT that is required for basal transcription of mitochondrial DNA (PubMed:29149603). In this complex, TFAM recruits POLRMT to a specific promoter whereas TFB2M induces structural changes in POLRMT to enable promoter opening and trapping of the DNA non-template strand (PubMed:20410300). Required for accurate and efficient promoter recognition by the mitochondrial RNA polymerase (PubMed:22037172). Promotes transcription initiation from the HSP1 and the light strand promoter by binding immediately upstream of transcriptional start sites (PubMed:22037172). Is able to unwind DNA (PubMed:22037172). Bends the mitochondrial light strand promoter DNA into a U-turn shape via its HMG boxes (PubMed:1737790). Required for maintenance of normal levels of mitochondrial DNA (PubMed:19304746, PubMed:22841477). May play a role in organizing and compacting mitochondrial DNA (PubMed:22037171).

Involvement in disease

Mitochondrial DNA depletion syndrome 15, hepatocerebral type

MTDPS15

An autosomal recessive mitochondrial disorder characterized by severe intrauterine growth restriction, neonatal-onset hypoglycemia and liver dysfunction, mitochondrial DNA depletion in liver and skeletal muscle, and abnormal mitochondrial morphology observed in skeletal muscle. Hepatic pathology includes cirrhosis, steatosis and cholestasis. Progression to liver failure and death is rapid with no evidence of neurological impairment or other organ involvement.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Phosphorylation by PKA within the HMG box 1 impairs DNA binding and promotes degradation by the AAA+ Lon protease.

Cellular localization

Alternative names

TCF6, TCF6L2, TFAM, mtTFA, Mitochondrial transcription factor 1, Transcription factor 6, Transcription factor 6-like 2, MtTF1, TCF-6

swissprot:Q00059 omim:600438 entrezGene:7019